Business
How to Capitalize on the $1 Billion Hemp Industry -- CFN Media
How to Capitalize on the $1 Billion Hemp Industry -- CFN Media.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n \n \n How to Capitalize on the $1 Billion Hemp Industry -- CFN Media\n \n \nHow to Capitalize on the $1 Billion Hemp Industry -- CFN Media\n \n SEATTLE, WA--(Marketwired - Sep 11, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering the explosive growth of the hemp industry and Medical Marijuana Inc.'s (OTC PINK: MJNA) pole position in the race to capitalize on it.\n The cannabis industry may be on track to surpass $50 billion by 2026, but that doesn't mean that investors should ignore the nascent hemp industry. With a projected 55% compound annual growth rate, the hemp industry is projected to surpass $1 billion in just three years. Analysts are bullish on the prospects for the industry, but note that there are few companies that have generated tangible revenues in the space.\n Hemp Set to Grow 55% Each Year to $1 Billion\n The cannabis industry is projected to reach $50 billion by 2026, according to Cowen & Co., driven by the legalization of recreational marijuana in California and Nevada. In addition to state-wide legalization, there are signs that the federal government could reverse its standing on medical marijuana under President Trump. A reclassification of the drug could lead to significant involvement from the multi-billion dollar pharmaceutical industry.\n While tetrahydrocannabinol (THC) gets most of the attention, a growing body of research has been focused on non-psychoactive cannabidiol (CBD). CBD has shown early promise in treating everything from Alzheimer's diseases to stroke and traumatic brain injury. GW Pharmaceutical plc has also successfully conducted clinical trials of Sativex -- a whole-plant CBD-rich extract -- for patients suffering from neuropathic pain.\n A new report by Brightfield Group projects that the hemp-derived cannabidiol market will be a billion-dollar market in three years. Brightfield estimates that hemp-based CBD sales surpassed $170 million last year and projects 55% compound annual growth that will increase that figure past the $1 billion mark. A key benefit of CBD over THC is that the cannabinoid is non-psychoactive and can be derived from hemp plants which makes it legal to sell anywhere.\n Medical Marijuana Inc.'s Unique Advantage\n Brightfield anticipates strong growth in ...